Robert L. Coleman, MD, FACOG, FACS

Articles

Future Outlook of Advanced Ovarian Cancer Treatment

May 30th 2023

Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.

Advanced Ovarian Cancer: Current Treatment Landscape in Second- and Later-Line Settings

May 30th 2023

Expert oncologists review the current PARP inhibitor treatment indications for patients with advanced ovarian cancer and discuss how to best manage patients who have been impacted by the recent updates to the PARP inhibitors.

Advanced Ovarian Cancer: Updated Indications for PARP Inhibitors in Second- and Later-Line Settings

May 30th 2023

Drs Coleman and Monk discuss what led to the recent withdrawal of several indications for PARP inhibitors in the treatment of advanced ovarian cancer.

Role of PARP Inhibitors in Advanced Ovarian Cancer

May 30th 2023

Expert oncologists give an overview of PARP inhibitors available for the treatment of patients with advanced ovarian cancer and review adverse events seen with each agent.

Role of Biomarkers in Advanced Ovarian Cancer

May 30th 2023

Experts on advanced ovarian cancer give detailed insights on the role of biomarker testing and identify important biomarkers.

Overview of Advanced Ovarian Cancer

May 30th 2023

Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide an overview of advanced ovarian cancer and discuss its prevalence and diagnosis process.

Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2023

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

Key Data Highlights in Ovarian Cancer

November 17th 2022

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.

Treatment of Rare Tumors in Ovarian Cancer

November 17th 2022

Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.

Investigative Therapies in Recurrent Ovarian Cancer

November 10th 2022

A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.

Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer

November 10th 2022

Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.

Antibody-Drug Conjugates in Ovarian Cancer Treatment

November 4th 2022

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer

November 4th 2022

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

PARP Inhibitor Resistance in Ovarian Cancer Treatment

October 27th 2022

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.

Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment

October 27th 2022

A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.

The Rationale for PARP Inhibition plus IO in Ovarian Cancer

October 20th 2022

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial

October 20th 2022

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.

Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial

October 17th 2022

Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.

PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer

October 17th 2022

Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.

PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial

October 6th 2022

Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.